Affymetrix and Abbott Enter Into Licensing Agreement
SANTA CLARA, Calif.–Affymetrix Inc. (Nasdaq:AFFX) announced that Abbott Molecular, a division of Abbott, has obtained a non-exclusive, worldwide license to a number of Affymetrix patents that will allow it to manufacture and sell comparative genomic hybridization (CGH) microarrays, related readers and software in the research and diagnostics field. Details of the license were not disclosed.